Resumen
Immune checkpoint inhibitors have improved the tumor response and survival of patients with metastatic renal cell carcinoma. However, no predictive factor of response to immunotherapy is currently available. The aim of our study was to evaluate metabolism, assessed with resting energy expenditure as a biomarker of response, in patients with metastatic renal cell carcinoma treated with nivolumab. We found that the 15 patients (29% of the cohort) that had hypermetabolism also had decreased tumor control and tended to have a worse overall survival compared to patients with normal or low metabolism. We conclude that the measurement of resting energy expenditure could help identify patients who will benefit most from immunotherapy in metastatic renal cell carcinoma.